This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (291)

Published on in Vol 9, No 4 (2020): April

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16664, first published .
Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial

Authors of this article:

Peter A Merkel1, 2 Author Orcid Image ;   David R Jayne3 Author Orcid Image ;   Chao Wang4 Author Orcid Image ;   Jan Hillson5 Author Orcid Image ;   Pirow Bekker5 Author Orcid Image
Article Authors Cited by (47) Tweetations (8) Metrics

Peter A Merkel   1, 2 , MD, MPH ;   David R Jayne   3 , MD ;   Chao Wang   4 , PhD ;   Jan Hillson   5 , MD ;   Pirow Bekker   5 , MD

1 Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States

2 Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, United States

3 Department of Medicine, University of Cambridge, Cambridge, United Kingdom

4 Biostatistics, Pharma Data Associates, LLC, Piscataway, NJ, United States

5 Research and Development, ChemoCentryx, Inc, Mountain View, CA, United States

Corresponding Author:

  • Peter A Merkel, MD, MPH
  • Division of Rheumatology
  • Department of Medicine
  • University of Pennsylvania
  • 5th Floor, White Building
  • 3400 Spruce Street
  • Philadelphia, PA, 19104
  • United States
  • Phone: 1 215 614 4401
  • Fax: 1 215 614 4402
  • Email: pmerkel@upenn.edu